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Summary Extracts from Pygeum africanum are used in
the treatment of prostatitis, benign prostatic hyperplasia
(BPH) and prostate cancer (PCa). The ligand-activated
human androgen receptor (AR) is known to control the
growth of the prostate gland. Inhibition of human AR is
therefore a major goal in treatment of patients. Here, we
characterize the compound N-butylbenzene-sulfonamide
(NBBS) isolated from P. africanum as a specific AR
antagonist. This antihormonal activity inhibits AR- and
progesterone receptor- (PR) mediated transactivation, but
not the related human glucocorticoid receptor (GR) or the
estrogen receptors (ERα or ERβ). Importantly, NBBS
inhibits both endogenous PSA expression and growth of
human PCa cells. Mechanistically, NBBS binds to AR and
inhibits its translocation to the cell nucleus. Furthermore,
using a battery of chemically synthesized derivatives of NBBS
we revealed important structural aspects for androgen antag-
onism and have identified more potent AR antagonistic
compounds. Our data suggest that NBBS is one of the active
compounds of P. africanum bark and may serve as a naturally
occurring, novel therapeutic agent for treatment of prostatic
diseases. Thus, NBBS and its derivatives may serve as novel
chemical platform for treatment prostatitis, BPH and PCa.
Keywords Antihormone . Prostate cancer . N-butylbenzene-
sulfonamide . Natural compound . Pygeum africanum .
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Abbreviations
AR Human androgen receptor
BPH Benign prostate hyperplasia
CPA Cyproterone acetate
C4-2 a LNCaP derivative cell line that exhibits
androgen-independent growth
CV1 Kidney cell line from green monkey, lacking
endogenously expressed functional AR, GR,
ER, PR and TR
DHT Dihydrotestosterone, androgen agonist
E2 Estradiol
ER Human estrogen receptor
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GFP Green fluorescent protein
GR Human glucocorticoid receptor
HBD Hormone binding domain
LNCaP a human prostate cancer cell line, exhibits
hormone-dependent growth
LacZ β-galactosidase expression vector used for
normalization of transfection efficiency
Luc Luciferase
MMTV Mouse mammary tumor virus
NBBS N-butylbenzene-sulfonamide
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OH-F Hydroxyflutamide, androgen antagonist
PCa Prostate cancer
PC3 a human prostate cancer cell line, lacking
endogenously expressed functional AR
PC3-ARwt stable transfected PC3 cell line, expressing
human wild type AR
PSA Prostate specific antigen
PR Human progesterone receptor
qRT-PCR Real time reverse transcription polymerase
chain reaction
R1881 Methyltrienolone, androgen agonist
RLU Relative light units (normalized to internal
control)
T3 Thyroid hormone (3,5,3′-triiodothyronine)
TR Thyroid hormone receptor
(DR4)2 Two direct repeats as known TR response
elements
Introduction
Benign prostate hyperplasia (BPH) and prostate cancer
(PCa) are serious health problems worldwide and PCa is the
second leading cause of cancer mortality of men in western
countries [1–3]. Due to the increase in life span of men the
occurrence of PCa is increasing steadily [4, 5]. The current
therapies have significant limitations since the tumour
eventually becomes resistant to the therapy [6]. Therefore
the development of new therapies against PCa is a major
challenge.
Many factors affect risk of developing PCa, important
being age and the circulating male androgens [7]. With
advancing age the prostate gland increases in size leading
often to BPH. In addition older men develop more chances
for having a diagnosis for PCa. Similarly, proliferation of
prostate and PCa is enhanced by androgens [3, 5, 8].
The current therapies have the goal to inactivate the
androgen receptor (AR). The AR regulates male sex differen-
tiation, is responsible for male fertility and promotes the
growth of normal prostate gland but also promotes the
proliferation of cancer cells of the prostate and therefore has
become the most important drug target for PCa therapy [5, 9].
The AR induces the expression of AR-responsive genes,
when it is bound to androgens. The inactivation of AR is
achieved by reducing androgen production and by treating
with androgen antagonists. So far synthetic androgen
antagonists are used for therapies: Hydroxyflutamide
(OH-F), casodex (bicalutamide) and cyproterone acetate
(CPA). These clinical strategies have the major goal to
inactivate the transactivation of human AR.
However, eventually during the therapy the cancer regrows
exhibiting resistance to this hormone ablation therapy. It has
been found that AR is present and still remains active and
promotes growth of prostate cells despite the treatments aimed
at inactivating the receptor [7, 9, 10].
How the receptor becomes reactivated despite the therapy
remains largely unclear. One mechanism is based on the
findings that AR becomes mutated. These mutations often
lead to a receptor that has gained the ability to promiscuously
bind also to non-androgenic ligands and therefore can be
activated by other ligands [11, 12] and thus bypassing the
androgen ablation or hormone therapy by androgen antago-
nists. For example, the mutation T877A of human AR,
isolated from PCa patients, renders the complete antagonist
OH-F to an agonist that activates AR [13–15].
A lipophilic extract from the bark of Pygeum africanum
(Tadenan®) is a plant-derived drug, which is commonly used
to prevent and treat BPH and PCa [16, 17]. The bark of
Pygeum africanum [18], an evergreen tree growing in Africa
is traditionally used to treat the “old men disease”. The bark
of Pygeum africanum is licensed in Italy, France and other
European countries for the treatment of symptomatic BPH.
This extract was shown to reduce prostate size in rats [19].
In this study we aimed to gain some insights into the
action of the compound N-butylbenzene-sulfonamide
(NBBS), which we have previously isolated from bark
extracts of P. africanum [20].
Materials and methods
Plant materials
Bark material of Pygeum africanum was a gift of Euromed
S.A., Barcelona, Spain. A voucher specimen (No. 8438102)
is deposited at the Department of Pharmaceutical Chemis-
try, Philipps-University of Marburg, Germany. The extract
preparation has been described elsewhere [20].
Chemicals and hormones
Dexamethasone, progesterone, 3,5,3′-triiodothyronine (T3),
dihydrotestosterone (DHT), estradiol (E2) and NBBS were
obtained from Sigma. Methyltrienolone (R1881) was
obtained from Perkin Elmer and hydroxyflutamide (OH-F)
from LKT Laboratories, Inc. All test compounds were
dissolved in ethanol or/and dimethylsulfoxide (DMSO),
except T3, which was dissolved in 50 mM NaOH. These
compounds were added to the culturing medium such that the
final concentration of ethanol and/or DMSO did not exceed
0.1%. Control incubations (no test compounds) were per-
formed in the presence of only 0.1% ethanol and/or DMSO.
All chemicals used for synthesis of NBBS derivatives
were obtained from Aldrich Chem. Co. USA, except of 4-
Fluorobenzenesulfonylchloride obtained from Acros
Organics, USA, that was used for the synthesis of S6.
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General procedure for the synthesis of the sulfonamides
S1-S14
0.2 moles of the primary amine were stirred at room
temperature under solvent-free conditions and 0.1 mol of
the corresponding arylsulfonyl chloride was added drop-
wise (development of heat). After cooling down, 100 ml of
water were added and the reaction product was extracted
with methylene chloride (3×50 ml). The solvent was
evaporated to give the pure product (yield 95–100%).
S
OO
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RNH
2
S
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N
H
R
NR
H
H
H
Cl+ +
2 + -
Nomenclature according to IUPAC
S1 N-Methylbenzene-sulfonamide
S2 N-Ethylbenzene-sulfonamide
S3 N-n-Propylbenzene-sulfonamide
NBBS N-n-Butylbenzene-sulfonamide
S4 N-Geranylbenzene-sulfonamide
S5 N-n-Butyl-4-Toluene-sulfonamide
S6 N-n-Butyl-4-Fluorbenzene-sulfonamide
S7 N-2-Hydroxyethylbenzene-sulfonamide
S8 N-2-Hydroxyethyl-4-fluorobenzene-sulfonamide
S9 N-n-Pentylbenzene-sulfonamide
S10 N-n-Butyl-3-trifluormethylbenzene-sulfonamide
S11 N-Geranyl-3-trifluormethylbenzene-sulfonamide
S12 N-n-Laurylbenzene-sulfonamide
S13 N-n-Butyl-3-trifluormethyl-4-nitrobenzene-
sulfonamide
S14 N-Geranyl-3-trifluormethyl-4-nitrobenzene-
sulfonamide
Plasmids
The plasmid pMMTV-luc, which contains a luciferase
reporter gene driven by the mouse mammary tumor virus
long terminal repeats responsive to androgens, is described
in reference [21]. The expression vector for the human AR
or AR T877A, pSG-hAR or pSG-hAR T877A and deletions
are described in reference [22]. The plasmid (DR4)2-tk-luc
is described in reference [23], for expression of human GR
in reference [24] and human TRβ in reference [25]. Human
PR1 and PR2 expression vectors were kindly provided by
P. Chambon (Strasbourg, France), human ERα and ERβ
expression vectors by L.C. Murphy (Manitoba, Canada),
and the reporter p3ERE-TATA-luc by D.M. Heery
(Nottingham, UK).
Reporter assays
CV1 cells were seeded onto 6-well tissue culture plates
(Nunc, Roskilde, Denmark) at 1.2×105 cells per well and
grown in DMEM (Invitrogen) supplemented with 10% (v/v)
dextran-coated charcoal stripped serum and 1% (v/v) penicil-
lin and streptomycin [26]. Six hours later cells were trans-
fected by using the CaPO4 method [22]. The DNA mixture
for transfections consisted of 1 µg of the appropriated
luciferase reporter constructs, 0.2 µg of the appropriated
mammalian steroid receptor expression vector and 0.2 µg of
the cytomegalovirus (CMV)-driven β-galactosidase expres-
sions vector, as internal control for transfection efficiency.
For the transient transfection experiments with the
ER-receptors, the culture medium of the stock cells was
changed to phenol-red-free DMEM (Invitrogen) supple-
mented with 10% (v/v) dextran-coated charcoal stripped
serum, 1% (v/v) glutamine, 1% (v/v) sodium pyruvate and
1% (v/v) penicillin-streptomycin. After 7 days, cells were
seeded into six-well plates at 1.5×105 per well. Twenty-four
hours later cells were transfected by using the CaPO4 method
[22] with 2 µg reporter plasmid, 0.2 µg receptor expressions
vector and 0.2 µg of the cytomegalovirus (CMV)-driven
β-galactosidase for normalization. After 14 h media were
replaced either with or without the addition of the appropri-
ate hormones together with the indicated compounds. After
additional 48 h cells were harvested and assayed for
luciferase and β-galactosidase activity. All transfection
assays shown were performed in duplicate and were repeated
at least twice.
Cell growth assays
Human prostate carcinoma LNCaP cells [27] were cultured in
RPMI-1640 medium (Invitrogen), supplemented with 10%
(v/v) fetal calf serum (FCS) (Invitrogen), 1% (v/v) penicillin
and streptomycin (Invitrogen), 1% (v/v) L-glutamin
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(Invitrogen), 1% (v/v) sodium pyruvate (Sigma). PC3, PC3-
ARwt were kindly provided by Dr. A. Cato, Karlsruhe,
Germany [28] and were cultured in DMEM supplemented
with 10% (v/v) FCS, 1% (v/v) penicillin and streptomycin
and 1% (v/v) L-glutamin. PC3-ARwt medium was supple-
mented with 600 µg/ml geneticin (Invitrogen). C4-2 cells
[29] were cultured in DMEM supplemented with 10% (v/v)
FCS, 20% F12 (Sigma), 5 µg/ml Insulin, 13.6 pg/ml T3
(Sigma), 5 µg/ml apotransferrin (Sigma), 0.25 µg/ml
Biotin (Sigma), 1% (v/v) penicillin and streptomycin.
For cell growth assays, cells were seeded onto 24-well
tissue culture plates (Nunc, Roskilde, Denmark) at 5×
103 cells per well in appropriated medium in triplicates
containing 5% FCS. On day 2, cells were fed with fresh
medium and treated with ethanol/DMSO or with the
indicated hormones or compounds. Every second day the
media was replaced with fresh media together with freshly
added compounds. The cells were trypsinized and counted
using a counting cell chamber (Double Neubauer, Brand,
Germany) at the indicated times.
Nuclear extract preparation
When LNCaP cells reached 50% confluency, they were
washed three times in PBS and the medium was
replaced by RPMI-medium supplemented with 2% (v/v)
charcoal-dextran-stripped FCS. After 3 days of cultiva-
tion the cells were treated with the indicated hormones
for 1 h.
For extract preparation the cells were washed twice
with ice cold PBS, were harvested with 1 ml PBS and
centrifuged at 1,000 g for 5 min at 4°C. The cell pellet
was resuspended in three volumes of hypotonic buffer A
(20 mM HEPES, pH 7.9, 10% glycerol, 0.2% Nonidet
P-40, 10 mM KCl, 1 mM EDTA, 0.1 mM PMSF, 1 mM
DTT) for 7 min on ice followed by centrifugation at
3,000 g for 10 min at 4°C. The cytoplasmatic supernatant
was removed and the nuclei pellet resuspended in two
volumes buffer B (420 mM NaCl, 20 mM HEPES, pH 7.9,
10 mM KCl, 1 mM EDTA, 0.1 mM PMSF), followed by
rotational incubation for 40 min at 4°C. To remove cell
debris, the extract was centrifuged at 12,000 g for
15 min at 4°C. The supernatant was transferred into a new
tube and diluted with three volumes of buffer C (10 mM
KCl, 20 mM HEPES, pH 7.9, 1 mM EDTA, 0.1 mM
PMSF). The cytoplasmic and nuclear extracts were
separated on SDS-PAGE and blotted onto a PVDF-
membrane (Millipore). Western blot analysis was per-
formed by using a mouse anti-AR antibody (F39.4.1,
BioGenex Laboratories) and the enhanced chemilumines-
cence detection method (Amersham Pharmacia Biotech).
The rabbit anti-GAPDH antibody was obtained from
abcam (ab9485).
Whole cell binding assay [30]
COS-7 cell were maintained in DMEM, supplemented with
10% FCS, 1% (v/v) penicillin and streptomycin in a
humidified 5% CO2 incubator. Cells were seeded into
24-well tissue culture plates (Nunc, Roskilde, Denmark) at
5×104 cells per well and grown in phenol-red-free DMEM
supplemented with dextran-coated charcoal-stripped serum
(5%). On day 2, cells were transfected (GeneJuice
Transfection reagent, Novagen) with 0.75 μg pSG5-flag-
wtAR expression vector, in accordance with the manufac-
turer’s instructions. On day 4, the cells were incubated for
90 min at 37°C with 1 nM [H3] mibolerone in the absence
and presence of an increasing concentration of either
unlabelled mibolerone or NBBS. Working on ice, cells
were washed three times with ice-cold 1×PBS for 15 min.
Cells were then lysed with 200 μl 1×passive lysis buffer
(Promega). Lysates were briefly centrifuged and total
binding was determined for 150 μl of cellular extract by
scintillation counting. Non-specific binding was determined
as the counts obtained when cells were incubated with
1 nM [H3] mibolerone in the presence of 10,000×
unlabelled mibolerone. Specific bound mibolerone was
calculated as the difference between total and non-specific
binding. The reported values are averages of three
independent assays, with each condition performed in
triplicate. Data was plotted as percentage [H3]mibolerone
specifically bound.
Protein detection
25×103 LNCaP cells were seeded into RPMI medium
containing 5% FCS. After 24 h cells were incubated with
the indicated compounds at 37°C for additionally 3 days or
7 days. Proteins were extracted by scrapping cells in ice
cold PBS and pelleting cells by centrifugation at 1,000g for
5 min at 4°C. The cell pellet was resuspended in 500 µl
NP-40 lysis-buffer (0.1% SDS, 1% NP-40, 50 mM Tris,
pH 8, 150 mM NaCl, 5 mM ETDA, 1 mM PMSF). The
lysis was followed by 3 cycles of freeze (with liquid N2)
and thaw (37°C). The cell debris were removed by
centrifugation at 12,000 g for 15 min at 4°C. Equal
amounts of protein (10 µg) were separated on SDS-PAGE
and blotted onto a PVDF-membrane (Millipore). Western
blot analysis was performed by using a mouse anti-AR
antibody (F39.4.1, BioGenex Laboratories) and the en-
hanced chemiluminescence detection method (Amersham
Pharmacia Biotech).
For GFP-AR detection HeLa cells were grown in
DMEM with 10% heat-inactivated FCS. Transfection
experiments were performed using the CaPO4 method as
described previously [26]. Cells with 20% confluency were
seeded out in 10 cm dishes using DMEM supplemented
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with 10% charcoal-stripped FCS and transiently transfected
24 h later with 10 µg of the GFP-hAR expression plasmid
(a generous gift from Dr. O. Jänne, University of Helsinki,
Finland) together with 5 µg calf thymus DNA. After 1 day
the cells were washed twice with PBS and fresh medium
containing 10% charcoal-stripped FCS was added. 48 h
after transfection the cells were treated with NBBS (10−4M)
and/or R1881 (Methyltrienolone) (10−10M) for 1 h. Cells
were then analyzed using a fluorescence microscopy with a
FITC filter. As control, cell morphology of the same cells is
shown by phase contrast. Sets of 2–3×100 cells were
counted and the cytosolic/nuclear distribution of GFP
fluorescence was determined. The error represents devia-
tion of the mean.
Real time RT-PCR
The real time RT-PCR (qRT-PCR) was performed essen-
tially as described previously [31] with specific primers for
detection of PSA mRNA and beta-actin mRNA for
normalization. As modifications 1.28×106 cells were
seeded out directly in media containing 10% charcoal
stripped FCS. After 2 days cells were treated with 100 µM
NBBS or solvent (ethanol) or androgen (R1881) was added
to a final concentration of 50 pM.
Results
NBBS as a receptor specific androgen antagonist
Previously, we have described the isolation of NBBS from
the methylene chloride extract of Pygeum africanum [20].
NBBS exhibits antiandrogenic activity inhibiting ligand-
activated human AR (Fig. 1) using transient transfection
assays expressing human AR in CV1 cells with cotransfec-
tion of MMTV-luc, a well-known AR responsive promoter
[21]. To test specifically for the AR-mediated transactiva-
tion, CV1 cells were used, which lack the expression of
endogenous AR, GR and PR that all bind to and mediate
transactivation from the same response elements. As
control, cells were treated with the solvent itself and
compared to untreated. The data suggest that NBBS inhibits
the ligand-induced transactivation of human AR.
To test for the potency of NBBS, on one hand a
concentration series of androgen agonists and on the other
hand a concentration series of NBBS was applied.
Treatment of transfected cells with a concentration series
of the natural androgen dihydrotestosterone (DHT) lead to
significant hormone-dependent induction of the luciferase
reporter at 0.5 nM DHT and strong induction at 10 nM of
DHT (Fig. 2a). Addition of NBBS (100 µM) in the absence
of DHT did not affect the reporter activity. In line with that
cell viability assays NBBS did not reveal cytotoxicity (data
not shown). In the presence of DHT, however, addition of
100 µM of NBBS potently inhibited DHT-induced (10 nM)
AR-mediated transactivation.
Since DHT undergoes rapid turnover and the degrada-
tion products may give side-effects, we have also treated
cells with methyltrienolone (R1881), known to be a very
potent agonist ligand for human AR, leading to hormone-
dependent induction of the reporter. One reason for that is
the higher stability of R1881 compared to DHT, which can
be easily degraded in cells [32]. Consequently, R1881
treatment lead to a ligand-induced activation of the reporter
at lower concentrations as observed with DHT (Fig. 2b). At
low concentrations of R1881, in the range of 10 pM, NBBS
inhibited potently the AR mediated transactivation. At
concentrations of 0.1 nM of R1881, NBBS (100 µM)
inhibited significantly ligand-activated AR, whereas at
0.5 nM of R1881 NBBS was ineffective in repressing AR
transactivation (Fig. 2b) suggesting a potential competition
between R1881 and NBBS. Using a concentration series of
NBBS in the presence of 10 pM R1881 revealed that NBBS
potently inhibits liganded human AR at 10 µM and 100 µM
(Fig. 3a).
Although the hydrophobic DHT and R1881 are thought
to easily pass the cell membrane [33], the permeability and
thus the intracellular concentration of the more hydrophilic
NBBS is unclear. Therefore, on molecular level the efficacy
of NBBS may be higher. Taken together, our data strongly
5
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R
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 x
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no hormone
Androgen
Solvent control
EtOH/DMSO
NBBSno treatment
Fig. 1 Inhibition of androgen activity by NBBS isolated from
Pygeum africanum extracts. CV1 cells, lacking functional endogenous
AR were transfected with the expression vector for human AR and the
reporter MMTV-luciferase either untreated (white bars) or treated with
the androgen methyltrienolone (R1881; 3×10−10M final concentra-
tion; black bars). Luciferase values obtained were normalized to the
cotransfected internal control and indicated as relative light units
(RLU). In addition cells were treated with NBBS (100 µM), dissolved
in ethanol/DMSO (1:1) or with this solvent alone (Solvent control). As
further controls, cells were tested without solvent treatment
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suggest that NBBS is able to repress the transactivation of
human AR.
To reveal whether NBBS inhibits the transactivation of
the endogenously expressed AR in human PCa cells we
analyzed the endogenous expression of the prostate
specific antigen (PSA) a diagnostic marker for PCa and a
direct target gene of the AR using qRT-PCR normalized to
beta-actin expression. In line with our data, treatment of
both LNCaP and C4-2 PCa cells with 100 µM NBBS
resulted in inhibition of androgen-induced PSA expression
(Fig. 3b).
To analyze the receptor specificity of NBBS various
members of the nuclear hormone receptor superfamily were
used for reporter assays (Fig. 4). The closely related
members of AR are the GR and PR for which the
MMTV-reporter is also a suitable responsive reporter.
CV1 cells were chosen since they lack functional GR, PR,
ERs and thyroid hormone receptors (TR). 1 µM, 10 µM
and 100 µM of NBBS did not affect the glucocorticoid-
induced transactivation of human GR (Fig. 4a and
supplemental data). We decreased hormone levels to an
extent to still be able to obtain significant hormone-induced
transactivation. In case of human PR both forms were
tested, the PR-B form with a more potent transactivation
function and the PR-A form, which is generated by an
internal translation start site. NBBS inhibited the
progesterone-induced transactivation of the PR-B form
at 0.1 nM as well as the PR-A form (Fig. 4b and
supplemental data). Using the human TRβ, with a TR
responsive reporter addition of NBBS did not affect
significantly the thyroid hormone (T3) induced trans-
activation of TR at various thyroid hormone concentra-
tions (Fig. 4c and supplemental data). Similarly, NBBS
treatment seems not affect either of the estrogen receptors,
ERα and ERβ (Fig. 4d). This indicates that NBBS has a
strong preference for the AR and PR.
Growth inhibition of human PCa cells by NBBS
The growth of prostate cells and PCa cells is initially
dependent on androgens. To test whether the androgen
antagonism of NBBS affects cell growth we used the
human androgen-dependent PCa cell line LNCaP. Equal
numbers of LNCaP cells were seeded out and were
treated with 10 µM and 100 µM of NBBS as well as
the known AR antagonist hydroxyflutamide (OH-F) in
5% normal serum that is known to naturally contain
androgens. Already at day 5, cells treated with 100 µM
NBBS exhibited a significant reduced growth (Fig. 5a).
The growth inhibitory effect was more prominent at day
8 of treatment. In the presence of 10 µM NBBS the
LNCaP cells revealed a reduced growth at day 8, whereas
treatment with OH-F did not show growth inhibition.
This may be due to the known fact that LNCaP cells
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Fig. 2 NBBS inhibits the
transcriptional activity of human
AR activated by DHT or the
synthetic agonist R1881. Cells
were tested in the AR activity
based assay described in Fig. 1
with a concentration series of
each androgen together with
100 µM NBBS (black bars) or
with the solvent control (white
bars). a Human AR was
activated by the natural hormone
dihydrotestosterone (DHT) or b
by methyltrienolone (R1881) at
the indicated concentrations
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have a point mutation in the hormone-binding domain
(HBD) of the human AR (T877A) that prevents OH-F for
being an antiandrogen rather a potent agonist in these
cells [13, 15].
Furthermore, we addressed the question whether the
androgen-independently growing C4-2 PCa cell line is also
growth reduced by NBBS treatment (Fig. 5b). Interestingly,
treatment of C4-2 cells with NBBS potently inhibits the
growth also of these cells to a similar extent as was
observed for LNCaP cells. This indicates that NBBS is
able to inhibit androgen-independent PCa cells.
To verify this finding, the androgen-independently
growing human PCa PC3-ARwt cells were used expressing
the wild-type human AR protein from a stable expression
vector integrate [28]. Similarly, the growth of these cells
was inhibited with NBBS treatment (Fig. 5c). As control
the parental PC3 cells, that lack the expression of wild-type
AR, were tested for the efficacy of NBBS to affect their
proliferation. Here notably, applying NBBS did not
significantly affect the growth of PC3 cells (Fig. 5d). This
suggests that NBBS inhibits specifically growth of PCa
cells expressing the mutant or wild-type AR further
supporting its role as an AR-antagonist.
To test whether NBBS might affect the stability of AR,
Western blot analyses were performed with LNCaP cells
treated for 3 days or 7 days without (control) or with NBBS
(supplemental data) with anti-AR antibodies. Interestingly,
neither treatment with 10 μM nor 100 μM resulted in a
reduced amount of AR (supplemental data) suggesting that
NBBS-mediated inhibition of AR transactivation is not
regulated through AR protein stability.
Taken together, these findings indicate that inhibition of
proliferation by NBBS is mediated through human AR and
is effective also for androgen-independently growing PCa
cells. In addition these data suggest that the inhibition of
proliferation of NBBS is also effective for cells expressing
the AR-T877A mutant, which is not significantly inhibited
by OH-F [13–15].
NBBS binds to AR and inhibits its nuclear translocation
To analyze the underlying mechanism of NBBS-mediated
inhibition of AR transactivation we first employed AR
deletion mutants. Since both LNCaP and C4-2 cells were
inhibited in growth and both cell types harbor the mutant
AR T877A we analyzed whether the transactivation of this
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Fig. 3 NBBS inhibits ligand
activated human AR and PSA
expression in human PCa cell
lines. a Increasing
concentrations of NBBS were
tested for its ability to inhibit
methyltrienolone (10−11M)
activated human AR with the
experimental setup described in
methods and Fig. 1. As control
cells were treated with the
solvent alone. b NBBS (10−4M)
inhibits the PSA expression in
human PCa cell lines.
Endogenously expressed PSA
mRNA levels were detected
using qRT-PCR and values were
normalized to the expression of
beta-actin. Left panel: qRT-PCR
with androgen-dependent
growing LNCaP cells. Right
panel: qRT-PCR with
androgen-independent growing
C4-2 cells
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AR mutant can be suppressed by NBBS. Cotransfection
experiments in CV1 cells revealed that the mutant AR
T887A-mediated transactivation is also repressed by NBBS
(Fig. 6a) suggesting that NBBS acts distinct from the
antagonist OH-F, which activates this AR mutant [13–15]
(and own observation).
To reveal whether the HBD of AR is necessary for
NBBS mediated suppression AR-deletions were employed
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Fig. 4 NBBS inhibits specifically human AR and PR. Other members
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(Fig. 6a, right panel). Deletion of the HBD leads to a
hormone-independent transactivation of AR [22], which
however, cannot be suppressed by NBBS, indicating that
the HBD is required for NBBS-mediated antagonism.
Deletion of the first 171 amino acids of the AR resulted
in reduced transactivation that was inhibited by NBBS
(Fig. 6a, left panel). The deletion of the entire N-terminus is
transcriptional inactive, which is in line with previous
observations that the major transactivation domain is
localized in the AR amino-terminus [22, 34–36] and thus
NBBS is unable to inhibit. These data suggest that the HBD
is required for the NBBS mediated inhibition of AR
transactivation.
Based on the requirement of the AR HBD for NBBS
action we wanted to determine whether NBBS is able to
compete for hormone binding. Therefore, competitive
whole cell binding assays with AR and radioactive labeled
mibolerone were performed (Fig. 6b). Mibolerone is known
to bind to the AR HBD hormone pocket. Replacement of
mibolerone leads to a reduced amount of radioactive
material bound to AR. As control, unlabeled mibolerone
was used. Treatment of AR with increasing amount of
NBBS indeed resulted in a decrease of mibolerone binding
(Fig. 6b) at concentrations that were also active in the
previous experiments (Figs. 3 and 6a). This suggests that
NBBS binds to the HBD of AR and confirms our previous
results.
Further, to analyze for NBBS-mediated antagonism the
involvement of corepressors were analyzed. Androgen
antagonists are known to recruit corepressors for suppres-
sion of AR mediated transactivation [22, 37–39]. However,
we did not find corepressor interaction with NBBS
0
5
10
15
20
25
30
35
1 5 8
Control
10-7M OH-F
10-5M NBBS
10-4M NBBS
To
ta
l n
um
be
r o
f c
el
ls
 (x
10
4 )
Days of treatment
LNCaP
a
b C4-2
0
2
4
6
8
10
12
14
16
1 4 8
DMSO/EtOH
OH-F (10-7 M) 
NBBS (10-4 M)
To
ta
l n
um
be
r o
f c
el
ls
 (x
10
3 )
Days of treatment
c PC3-ARwt
5
10
15
20
25
1 4 8
To
ta
l n
um
be
r o
f c
el
ls
 (x
10
3 )
Days of treatment
DMSO/EtOH
OH-F (10-7 M) 
NBBS (10-4 M)
d PC3
5
10
15
20
25
30
35
40
1 4 8
DMSO/EtOH
OH-F (10-7 M) 
NBBS (10-4 M)
To
ta
l n
um
be
r o
f c
el
ls
 (x
10
3 )
Days of treatment
Fig. 5 NBBS inhibits growth of the prostate cancer cell line LNCaP,
C4-2 and PC3-ARwt. Two different concentrations of NBBS (10 µM
and 100 µM) were tested for the ability to influence growth of the
model human PCa cell line LNCaP (a), 100 µM of NBBS for C4-2 (b)
and PC3-AR (c) cells. PC3 cells lacking AR expression were used as
control (d). Equal amounts of cells were seeded out and were either
treated with NBBS, the known androgen antagonist hydroxyflutamide
(OH-F), or solvent control. The number of cells was counted at the
indicated days
Invest New Drugs
treatment using the classical modified mammalian two-
hybrid system employing SMRT, NCoR and Alien ([22, 40]
and data not shown). Then we addressed another hypothet-
ical possibility to repress AR transactivation, which is the
inhibition of nuclear translocation [31]. For that purpose
endogenously expressed human AR was analyzed by
preparing cytosolic and nuclear fractions from the human
androgen-dependent PCa cell line LNCaP treated with
R1881 and without or with NBBS. Western analysis was
used to detect the localization of AR (Fig. 6c). Without
R1881 treatment the majority of AR showed cytosolic
localization and treatment with NBBS suggest no signif-
icant changes in the cytosolic-nuclear ratio. Treatment of
cells with R1881 resulted in detection of the majority of
AR in the nuclear fraction. Interestingly, combined
treatment of R1881 together with NBBS revealed that
the AR changed the ration of being more cytosolic and
less nuclear compared to agonist treatment alone
(Fig. 6c).
To further verify this finding the human AR was fused to
GFP. The GFP-AR fusion was expressed in HeLa cells and
tested whether NBBS affects the agonist-induced translo-
cation of AR into the nucleus by treating cells with R1881
and without or with NBBS (Fig. 6d). The AR-specific
agonist R1881-induced translocation of the GFP-AR fusion
into the nucleus, however, in combination with NBBS the
GFP-AR remained pre-dominantly in the cytoplasm. The
statistic analysis of the cytosolic and nuclear ratio of
GFP-AR staining further indicates that treatment with
NBBS alone does not affect AR translocation but
inhibits the agonist-induced translocation (Fig. 6e). Thus,
these data indicate that the agonist-induced translocation is
inhibited by treatment of cells with NBBS. This further
confirms that NBBS inhibits AR translocation into the
nucleus.
Thus, our data suggests that the molecular basis
of inhibition of AR transactivation by NBBS is to
suppress the hormone-induced translocation into the cell
nucleus.
NBBS derivatives as potential new antiandrogens
A battery of NBBS derivatives was chemically synthesized
to modify the butyl side chain and the benzene ring by
substitutions (Fig. 7). These compounds were employed for
their ability to act as AR antagonists in the cell culture
based assay. To test for potential higher efficient repression
of AR-mediated transactivation we compared the efficacy
of each compound at 10 µM concentration with that of
NBBS (Fig. 8). We used a higher concentration (3×
10−10 M) of R1881, at which NBBS lacked significant
inhibition of AR-mediated transactivation (Fig. 2b and data
not shown). The compounds S1–S3 and S5–S8 exhibited
no significant antiandrogenic effect. These modifications
included either shortening the butyl side chain (S1–S3 and
S7) or substitution of the benzene ring at the para-position
(S5, S6 and S8). This strongly suggests the importance of
the length of the side chain and an unsubstituted benzene
ring at the para-position as antiandrogenic compound
(Figs. 7a and 8a).
Interestingly, lengthening the side chain by replacing the
butyl side chain with a pentyl or a geranyl group (S4 and
S9) enhanced the antiandrogenic activity indicating that a
hydrophobic side chain is important for androgen antago-
nistic function. However, further extension of the side chain
by introducing a lauryl group (S12; Figs. 7b and 8b)
weakened the androgen antagonistic potency. This indicates
that enhancing the hydrophobicity alone is not sufficient to
enhance antiandrogenicity.
Notably, also substitutions at the meta-position of the
benzene ring enhanced androgen antagonistic activity (S10,
S11, S13 and S14; Figs. 7 and 8). Thus, through generation of
NBBS-derivatives enhancing hydrophobicity at the side chain
or substitutions at the meta-position of the benzene ring
the AR antagonism was potently enhanced suggesting
that NBBS can serve as a novel platform to generate
new AR antagonists.
To analyze whether derivatives exhibit a similar under-
lying mechanism as NBBS to inhibit the androgen-induced
translocation AR we performed a similar experimental
setup employing GFP-AR. According to NBBS, also the
more potent compounds S10 and S11 inhibited the AR-
mediated translocation (Fig. 8c) suggesting that NBBS
derivatives may be a useful tool to inhibit the AR at a step
prior its action in the nucleus.
Thus, it may be possible to generate even more potent
androgen antagonists based on natural bio-active chemical
structures as lead compounds.
Discussion
In the present study we have characterized the natural
compound NBBS as androgen antagonist. NBBS is very
effective at 100 µM concentration in cell culture systems. It
inhibits potently both the transactivation of human AR
induced by androgens and the growth of the human LNCaP
PCa cells. Due to the hydrophobicity the androgens DHT
and R1881 are thought to not require an active process to
enter the cytoplasm and to bind to AR [33]. NBBS is more
hydrophilic in nature and therefore the mode of cellular
uptake may not be comparable. Thus, the concentration of
NBBS used for treatment of cells and required for potent
inhibition does not necessarily reflect its intracellular
concentration. Other natural compounds were shown to
require a similar concentration range of action [41–46].
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Thus, our findings are in line with observations of other
groups using natural compounds. Also, it is possible that
NBBS may act in concert with other natural compounds
that enhance the androgen antagonism and growth
inhibition.
Interestingly, NBBS inhibits the growth of the human
PCa cell line LNCaP that were derived from lymph node
metastasis. These cells express a mutated human AR with
the consequences that the androgen antagonist OH-F
exhibits agonistic activity instead of inhibiting AR [13,
15]. This may be an important molecular mechanism of
how therapy resistance by treatment of patients with
androgen antagonists may occur. Since NBBS is able to
inhibit growth of LNCaP C4-2 and PC3-AR cells it may
serve as a tumor inhibitor despite the occurrence of therapy
resistance to other androgen antagonists. This may also lead
to the conclusion that NBBS might be used in addition to
other androgen antagonists or in combination with andro-
gen ablation therapy.
The obtained results suggest that the underlying mech-
anism of NBBS to inhibit AR transactivation is based on
suppression of nuclear translocation of AR. The currently
clinically used AR antagonists inhibit AR based on
mechanisms such as through recruitment of corepressors
or through changing chromatin accessibility [22, 37–39, 47,
48]. The novel mechanism described here may also allow in
future understanding better the structural features of AR to
undergo nuclear translocation.
In addition, the problem of therapy resistance of PCa that
eventually occurs during PCa development or selected
under cancer therapy, is in great part based on the AR that
becomes transcriptionally active despite antagonist treat-
ment. The underlying mechanisms include amplification or
mutations of the AR gene leading to mutant ARs that bind
in a more promiscuous manner other ligands. Also
discussed is the lack of corepressor binding to AR due to
activation of signaling pathways such as protein kinase A
or membrane tyrosine kinases (her/neu) [5, 22]. Reduced or
lack of corepressor binding abrogates AR inhibition by
androgen antagonists. A novel mechanism to inhibit AR
transactivation, such as by suppressing its nuclear translo-
cation, may allow treatment of patients that developed
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refractory PCa. Also, NBBS derivatives exhibited a similar
underlying mechanism to inhibit the androgen-induced
translocation of AR at a step prior the action of AR in the
nucleus.
Thus, NBBS may serve as a molecule to analyze novel
mechanisms to inhibit the AR transactivation and prostate
cell growth.
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